Health Care • Medical/Dental Instruments
$9.57 ▲ +0.33
(+3.57%)
MKT CAP: $527.2M • VOL: 346.5K
52W L $3 52W H $10
SGHT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $77.4M | $79.9M | $81.1M |
| YoY Revenue Growth % | -3.1% | -1.5% | — |
| Gross Profit | $66.7M | $68.3M | — |
| Gross Margin % | 86.2% | 85.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$37.1M | -$50.5M | -$57.3M |
| Operating Margin % | -48.0% | -63.3% | -70.7% |
| Net Income (GAAP) | -$38.4M | -$51.5M | -$55.5M |
| EBITDA (Normalized) | -$36.9M | -$50.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$29.7M | -$22.4M | -$47.2M |
| Capital Expenditures (CapEx) | $224.0K | $385.0K | — |
| Free Cash Flow (FCF) | -$29.9M | -$22.7M | -$47.2M |
| FCF Margin % | -38.7% | -28.5% | -58.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $92.0M | $120.4M | — |
| Total Debt (Short + Long Term) | $40.3M | $39.4M | — |
| Total Stockholders' Equity | $63.9M | $87.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SGHT.